The lack of venetoclax responses in BCL2-negative DLBCL supports the notion that the presence of BCL2 protein is required to obtain a response to venetoclax, and that patients who have BCL2-negative lymphomas may not benefit from venetoclax-based regimens. Here, BCL2 is linked to lymphoma.